Ezetimibe
Ezetimibe is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Ezetimibe; Generic name: EZETIMIBE; Drug class: Dietary Cholesterol Absorption Inhibitor [EPC].
| Brand name | Ezetimibe |
|---|---|
| Generic name | EZETIMIBE |
| Drug class | Dietary Cholesterol Absorption Inhibitor [EPC] |
| Manufacturer | ScieGen Pharmaceuticals Inc |
| Used for | 1 INDICATIONS AND USAGE Ezetimibe is indicated: In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia. In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediat |
| Dosage | 2 DOSAGE AND ADMINISTRATION The recommended dose of ezetimibe is 10 mg orally once daily, administered with or without food. If as dose is missed, take the missed dose as soon as possible. Do not double the next dose. Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ezetimibe. Administer ezetimibe at least 2 hours before or 4 hours after administration of a bile acid sequestrant [see Drug Interactions (7) ] . 10-mg orally once daily, with or without food ( 2 ) Admin |
| Active ingredient(s) | EZETIMIBE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11de499b-ad8a-46a6-9021-c8eba72ae414 |